by Blood Advances
Phase II evidence supports the use of post-transplant cyclophosphamide (PTCy) as prophylaxis against acute graft-versus-host disease (aGVHD) in patients undergoing hematopoietic cell...
by Blood Advances
Study data suggest donor age and HLA status influence outcomes in older patients receiving post-transplant cyclophosphamide as graft-versus-host disease prophylaxis following hematopoietic cell...
by Alex Kadhim
In a recent study, researchers from the University of California, San Francisco, have demonstrated that high exposure to melphalan significantly increases the risk of graft-versus-host disease...
by Blood
Researchers say analogous IL-17 and CSF-1 dysregulation signatures may help optimize the use of newly approved agents for the prevention and treatment of chronic graft-versus-host disease (cGVHD),...
by Blood
Rovadicitinib demonstrates therapeutic potential for patients whose chronic graft-versus-host disease (cGVHD) is glucocorticoid-refractory or -dependent, researchers report.
by Nature
Single-center data elucidate the benefits of using fludarabine and melphalan (FM) conditioning before peripheral blood stem cell (PBSC) transplantation and post-transplant cyclophosphamide (PTCy)...